Although aberrant methylation of CCDC181 was found in lung and prostate cancer in previous studies and in endometrial cancer in Taiwanese cohort, aberrant methylation of CCDC181 was a good cancer biomarker with high sensitivity (81.5%) in breast cancer. Here, CCDC181 is linked to prostate carcinoma.